Lactobacillus Reuteri DSM 17938 Versus Placebo in the Treatment of Infantile Colic
|ClinicalTrials.gov Identifier: NCT01541046|
Recruitment Status : Completed
First Posted : February 29, 2012
Last Update Posted : November 20, 2014
Infantile colic is a common medical condition which remains a frustrating problem for parents and health care providers with no clear treatment guidelines. To fill the void in existing literature, we present a protocol to examine whether probiotics are effective in decreasing infantile colic symptoms when compared to placebo treatment.
We hypothesize that oral administration of the probiotic L. reuteri DSM 17938 will reduce symptoms of infantile colic in breastfed infants in comparison to placebo.
An interim analysis will be conducted after 50 infants randomized to monitor both safety and efficacy.
|Condition or disease||Intervention/treatment||Phase|
|Colic||Biological: Biogaia L. reuteri DSM 17938 Biological: Probiotic Placebo||Phase 2|
Infantile colic is one of the most commonly reported medical problems within the first three months of life causing appreciable distress for both parents and pediatricians. The reported incidence of infantile colic ranges from 3% to 28% in prospective studies and up to 40% in retrospective surveys.
The pathogenesis of infantile colic remains elusive despite decades of research. It appears that multiple independent origins might be involved: amongst them infant's difficult temperament, inadequate mother-infant communication or maternal anxiety, transient lactase deficiency, exposure to cow's milk, abnormal gastrointestinal function, maternal smoking during pregnancy or after delivery. Consequently, various treatment approaches have been tried to alleviate this condition.
Recent studies have suggested that changes of intestinal microflora of a newborn may play an important role in pathogenesis of infantile colic. Therefore, dietary supplementation with probiotics has been proposed for the improvement of this condition.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||55 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Lactobacillus Reuteri DSM 17938 Versus Placebo in the Treatment of Infantile Colic: A Randomized Double-blind Controlled Trial|
|Study Start Date :||November 2011|
|Primary Completion Date :||June 2014|
|Study Completion Date :||June 2014|
Experimental: Biogaia L. reuteri DSM 17938
Biogaia L. reuteri DSM 17938, probiotic infant drops (5 drops=10^8 cfu),5 drops, once per day for 21 days.
Biological: Biogaia L. reuteri DSM 17938
Freeze-dried Lactobacillus reuteri DSM 17938 suspended in oil. Brand Name Active Agent: BioGaia™
Placebo Comparator: Probiotic Placebo
Placebo drops (sunflower oil, medium chain triglyceride oil, silicon chloride), 5 drops, once a day for 21 days.
Biological: Probiotic Placebo
Description of Placebo: contains same excipients as Active Agent, without the active ingredient
- Mean change in crying time [ Time Frame: Baseline, 7 days, 14 days, 21 days ]Reduction of daily median crying time (measured with parental diary) with L. reuteri DSM 17938 versus placebo at any of the time points 7, 14, and 21 days
- Number of responders vs. non-responders [ Time Frame: Baseline, at 7, 14 and 21 days ]Number of responders versus non-responders with L. reuteri versus placebo at the time points 7, 14, and 21 days. Responder is defined as a decrease in daily average crying time of 50% during the study as measured using the maternal daily diary.
- Parental quality of life [ Time Frame: Daily for 21 days ]Parental quality of life assessed by self-administered numerical rating scale from 0 (worst possible) to 10 (perfect well-being)
- Number of episodes of crying [ Time Frame: Over 21 days ]Reduction in the number of episodes of crying (measured with parental diary) with L. reuteri DSM 17938 versus placebo
- Duration of episodes of crying [ Time Frame: Over 21 days ]Reduction in the duration of episodes of crying (measured with parental diary) with L. reuteri DSM 17938 versus placebo
- Changes in stool consistency [ Time Frame: Over 21 days ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01541046
|The Hospital for Sick Children|
|Toronto, Ontario, Canada, M5V1X8|
|Principal Investigator:||Gideon Koren, MD||The Hospital for Sick Children|